BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Jesse Jackson hospitalized, under observation for a neurodegenerative condition - 2The Most Encouraging New companies to Look Out For
- 3The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- 4Find the Techniques for Powerful Review Propensities: Opening Your Scholarly Potential
- 5Vote in favor of your Number one Sort of Cap
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- New dinosaur tracks in Italy illustrate herds moving in unison
- Manual for Vegetarian Protein Powder
- Tremendous Spelunking: Cool Caverns All over the Planet
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- Why this Iranian island looks like Mars after it rains
- A Manual for Well known Western television Series
- The Most Moving TED Talks You Want to Watch
